Antipneumocystis activity of 17C91, a prodrug of atovaquone.
The prophylactic efficacy of 17C91, a carbamate prodrug of atovaquone (ATQ), was investigated in a severe combined immunodeficient mouse model of Pneumocystis carinii pneumonia (PCP). At an oral dosage equivalent to 100 mg of ATQ per kg of body weight per day, 17C91 protected 9 of 10 mice from PCP and had a prophylactic efficacy comparable to that of co-trimoxazole (at 250 mg of sulfamethoxazole plus 50 mg of trimethoprim per kg per day orally). The intensity of P. carinii infection (infection score) of mice treated with 17C91 correlated with the concentration of ATQ in the plasma, with clearance of the infection associated with plasma ATQ levels of >35 micrograms/ml. 17C91 given orally provided enhanced levels of ATQ in the plasma compared with the conventional ATQ formulation. Additional studies reported in this paper demonstrate that the prophylactic activity of 17C91 against PCP in severe combined immunodeficient mice is comparable to that of a new oral microparticulate formulation of ATQ.
Comley
J C
JC
Biology Division, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.
Yeates
C L
CL
Frend
T J
TJ
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D002219:Carbamates / Q000494:pharmacology*; D005260:Female; D051379:Mice; D016513:Mice, SCID; D009285:Naphthoquinones / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011355:Prodrugs / Q000627:therapeutic use*
D000935:Antifungal Agents; D002219:Carbamates; D009285:Naphthoquinones; D011355:Prodrugs; C097447:atovaquone prodrug 17C91; D053626:Atovaquone